At a glance
ClinicalIndex Comparison RecordN/ACompleted· 28 enrolled
Drug / intervention
Mejoral® 500 Tablets +1 moredrug
Likely dose
Mejoral® 500 Tablets 500 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Single Blinded, Two-period, Two-treatment, Crossover, Randomized, Single Dose Bioequivalence Study of Two Oral Formulations With 500 mg of Paracetamol (Mejoral® 500 Tablets, Glaxosmithkline méxico s.a. De c.v. Vs. Tylenol® Caplets, Janssen Cilag de méxico, s. De r.l. De c.v.) in Healthy Subjects Under Fasting Conditions
In Brief
A clinical study evaluating Mejoral® 500 Tablets and Tylenol® Caplets for Pain. Completed, enrolled 28 participants across 1 site.
Detailed Summary
This will be a monocentric, single blinded, randomized, single-dose, two-periods, two-sequence, crossover bioequivalence study of two oral formulations in healthy participants under fasting conditions.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPain
CountriesMexico
Collaborators--
Timeline
N/ACompletedFinished
20162017201820192020202120222023202420252026
First PostedJul 2015
Enrollment StartAug 2015
Primary CompletionAug 2015
Study CompletionAug 2015
TodayJul 2026
First PostedJul 22, 2015
Enrollment StartAug 1, 2015
Primary CompletionAug 1, 2015
Study CompletionAug 19, 2015
TodayJul 2, 2026
Enrollment to primary: 0 daysPosted 10.9 years ago
Interventions
Mejoral® 500 Tabletsdrug
500 mg tablet of paracetamol
Tylenol® Capletsdrug
500 mg tablet of paracetamol